Stockreport

Aravive Reports Preliminary Results of AVB-500 from the First Cohort of the Phase 1b/Phase 2 Recurrent Platinum Resistant Ovarian Cancer Trial

Aravive, Inc.  (ARAV) 
Last aravive, inc. earnings: 3/27 08:00 am Check Earnings Report
PDF AVB-500 in combination with standard of care demonstrates early proof of concept for anti-tumor activity in platinum-resistant ovarian cancer Aravive to expand enrollm [Read more]